In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targovax ASA

www.targovax.com

Latest From Targovax ASA

Targovax Pivots Towards Oncolytic Viruses

Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.

 

Cancer ImmunoOncology

Amphera Gears Up To Evaluate Dendritic Cells For Pleural Mesothelioma

Dutch biotech Amphera has progressed into late-stage clinical studies with dendritic cells activated with an allogeneic lysate of tumor cell lines; the dendritic cells are expected to have a therapeutic effect in patients with mesothelioma, a tumor with few treatment options.

 

Clinical Trials ImmunoOncology

Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program

Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.

Research and Development Strategies ASCO

Pipeline Watch: Phase III Progress With Bempedoic Acid, Lefamulin, And Ibrutinib Combo

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Targovax AS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Targovax ASA
  • Senior Management
  • Oystein Soug, CEO
    Erik Digman Wiklund, CFO
    Magnus Jaderburg, CMO
    Michael Bogenstaetter, PhD, CBO
  • Contact Info
  • Targovax ASA
    Phone: 213 98 810
    Lilleakerveien 2 C
    Oslo, NO-0283
    Norway
UsernamePublicRestriction

Register